Kara Beth Markham , MD

Bachelor's Degree: Denison University Granville, OH, 2001 (Biology)

Medical Degree: University of Michigan School of Medicine Ann Arbor, MI, 2005

Residency: The Ohio State University Columbus, OH, 2009

Fellowship: The Ohio State University Columbus, OH, 2012 (Maternal Fetal Medicine )

Master's Degree: The Ohio State University Columbus OH, 2018 (Bioethics)

American Board of Obstetrics and Gynecology (Maternal-Fetal Medicine) (Certification Date: 04-09-2014 ) - (Recertification Date: to 12-31-2023 )

American Board of Obstetrics and Gynecology (Certification Date: 12-07-2012 ) - (Recertification Date: to 12-31-2023 )

Gestational Diabetes

Maternal and Fetal Medicine

Obstetrics and Gynecology

Cervical insufficiency

Fetal growth restriction

Genetic abnormalities

Heart disease in pregnancy

Periviable birth

Preterm Labor

Twin Pregnancy

Twin to twin transfusion syndrome

Maternal and Fetal Medicine

Obstetrics and Gynecology

07-01-2012 -07-27-2018 Assistant professor, The Ohio State University Wexner Medical Center, Columbus, OH

08-01-2018 -To Present Associate Professor, University of Cincinnati College of Medicine, Cincinnati, OH

Grant: #80202135EBF0001 07-21-2023 -07-20-2026 Janssen Research & Development, LLC A Historical Cohort, Multicenter Study to Characterize the Management, Clinical Course, and Outcomes of Pregnancies in Women Who Have Experienced a Pregnancy With Early Onset Severe HDFN Role:PI 0.00 Hold Level:Industry

Grant: #80202135EBF0001 07-21-2023 -07-20-2026 Janssen Research & Development, LLC A Historical Cohort, Multicenter Study to Characterize the Management, Clinical Course, and Outcomes of Pregnancies in Women Who Have Experienced a Pregnancy With Early Onset Severe HDFN Role:PI 0.00 Hold Level:Industry

Grant: #8020135FEB3001 Azalea Investigators:Markham, Kara 09-23-2024 -09-23-2027 Janssen Research & Development, LLC A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus & Newborn Role:PI 2123821.45 Active Level:Industry

Peer Reviewed Publications

Stetson B, Scrape S, Markham KB (2017. ) Anti-M alloimmunization: Management and outcome at a single institution. .AJP Rep , , 7 ,e205-210

Markham KB, Scrape SR, Prasad M, Rossi KQ, O’Shaughnessy RW (2016. ) Hemolytic disease of the fetus and newborn due to intravenous drug use .AJP Rep, , 6 ,e129-32

Markham KB, Rossi KQ, Nagaraja HN, O’Shaughnessy RW (2015. ) Hemolytic disease of the fetus and newborn due to multiple maternal antibodies .Am J Obstet Gynecol , , 2123 (68 ) ,e1-5

Markham KB, Walker H, Lynch CD, Iams JD (2014. ) Preterm birth rates in a prematurity prevention clinic after adoption of progestin prophylaxis .Obstet Gynecol, , 123 (1 ) ,34-39

Moise KJ Jr, Hashmi SS, Markham K (2019. ) . Cell free fetal DNA to triage antenatal rhesus immune globulin: Is it really cos-effective in the United States?.Prenat Diagn , , 39 ((3): ) ,238 -239-247More Information

Lee, Alan J; Leonard, Anthony; Markham, Kara B (2022. ) Fetal and Neonatal Reticulocyte Count Response to Intrauterine Transfusion for the Treatment of Red Blood Cell Alloimmunization.Journal of pediatric hematology/oncology, , More Information

Forde, Braxton; Lim, Foong-Yen; McKinney, David N; Habli, Mounira; Markham, Kara B; Hoffman, Mallory; Tabbah, Sammy; Oria, Marc; Peiro, Jose L (2023. ) Association of amnioinfusion volume at the time of surgery for twin-twin transfusion syndrome and latency to delivery.Prenatal diagnosis, , 43 (9 ) ,1239-1246 More Information

Book Chapter

Markham KB, Fanaroff AA (2014 ) Obstetric Management of Prematurity, Chapter 20 10th Edition: Disease of the Fetus and Newborn .

Invited Presentations

Markham KB, Sansom SE, Kniss DA, Ackerman WE, Martin MM, Nuovo GJ, and Elton TS. (03-19-2011. ) MicroRNA-155 targets the Angiotensin II Type I receptor and is diminished in placentas from women with severe preeclampsia. .Concurrent Presentation: Society for Gynecologic Investigation 58th Annual Scientific Meeting, Miami, FL. Level:National

Poster Presentations

Markham KB, Moise KJ. (02-02-2018. ) Anti-Rh(D) Alloimmunization: Outcomes at a single institution. 38th Annual Society for Maternal-Fetal Medicine Pregnancy Meeting, Dallas, TX. . Level:National

Lee AJ, Hade EM, Markham KB (02-02-2018. ) Fetal and neonatal reticulocyte count response to intrauterine transfusion for the treatment of red blood cell alloimmunization. 38th Annual Society for Maternal-Fetal Medicine Pregnancy Meeting, Dallas, TX. . Level:National

alloimmunization. Poster Presentation: Society for Maternal Fetal Medicine 38th Annual Meeting, February 2, 2018, Dallas, TX. Stetson BT, Markham KB (01-26-2017. ) . Anti-M isoimmunization: Management and outcome at a single institution .37th Annual Society for Maternal-Fetal Medicine Pregnancy Meeting, Las Vegas, NV. . Level:Regional

Markham KB, Rath K, Paetow MS, Landon MB, Nankervis CA, Cordero L (05-01-2014. ) . Obstetrical management of non-diabetic pregnancies complicated by macrosomia .: Pediatric Academic Societies Annual Meeting, Vancouver. . Level:International

Markham KB, Rath K, Zheng K, Durnwald C, Thung S, Landon M, Cordero L (02-11-2013. ) Delivery outcomes of large for gestational age (LGA) infants of diabetic mothers (IDMs .Society for Maternal Fetal Medicine 33rd Annual Meeting. , San Francisco. . Level:Regional

Walker H, Lynch C, Markham K, Larma J, Ibrahim S, Tabbah S, Walton J, Johnson T, Iams J. (02-11-2013. ) Rate of preterm birth in a prematurity prevention clinic after adoption of progestin supplementation. Poster Presentation .Society for Maternal Fetal Medicine 33rd Annual Meeting, san francisco, CA. . Level:Regional

Markham KB, Hade E, Lynch C, Samuels P, Landon M. (02-02-2012. ) Advanced maternal age and the impact on birth weight. .Advanced maternal age and the impact on birth weight. Society for Maternal Fetal Medicine 32nd Annual Meeting, Dallas, TX. . Level:National

Markham KB, Rossi K, Lynch C, and O’Shaughnessy RW. (02-05-2010. ) The development of clinically significant hemolytic disease of the fetus and newborn due to anti-c combined with one or more additional red blood cell antibody .Society for Maternal Fetal Medicine 30th Annual Meeting, chicago, IL. .

Markham KB, Rossi K, Lynch C, and O’Shaughnessy RW (02-05-2010. ) The development of clinically significant hemolytic disease of the fetus and newborn due to anti-K combined with one or more additional red blood cell antibody. .Society for Maternal Fetal Medicine 30th Annual Meeting, chicago, IL. .

Academic - Medical Sciences Building
231 Albert Sabin Way
Cincinnati  Ohio, 45267-0526
Phone: 513-558-8448
Fax: 513-558-3558
markhakb@ucmail.uc.edu